CollabRx,
a leader in cloud-based expert systems to inform healthcare decision making, is
harnessing the knowledge of leading physicians, scientists and researchers from
the nation’s most prestigious academic and medical institutions to continue
development of its CancerRx™ app.
Currently
available for download on Apple’s App Store, CancerRx is designed to offer
expert guidance for physicians and their patients regarding the complex
landscape of oncology therapeutic options. The app provides helpful information
on the treatment options for lung cancer, melanoma, metastatic breast cancer
and colorectal cancer based on a variety of important clinical parameters.
While
treatment options based on current standards of care are presented by the app,
it also helps patients and physicians identify the most relevant clinical
trials and provides summaries to help users find the most applicable treatment
options for their individual needs. In an effort to stay current, CancerRx also
presents users with a daily newsfeed from MedPage Today, complete with
real-time, over-the-air updates.
As
social networks and the internet continue to provide floods of information to
patients on how to identify and act upon data that may be relevant to the
treatment of a particular cancer, CollabRx is doing its part to eliminate the
notable lack of online resources and tools available to provide specific,
personalized therapy considerations to physicians and patients. By creating
actionable and highly credible information sources, the company is able to best
serve its customers who are in the process of determining the best cancer
treatment plan.
The
company has made big moves in recent weeks, releasing two major public
offerings. In the first, CollabRx priced an offering of 3.84 million shares of
common stock at $1.25 per share with warrants to purchase up to an aggregate of
3.84 million shares with an exercise price of $1.56. In the second, the company
priced 2,362,205 shares of common stock at $1.27 per share, complete with an
additional 354,330 shares to cover any over-allotments. Between the two
offerings, the company expects gross proceeds of approximately $8.5 million,
which could help the company make significant strides toward organizing the
world’s knowledge in molecular medicine and making it universally acceptable
and useful.
CollabRx
works under the principle that optimal healthcare decisions are made when everyone
involved has access to the latest and most credible information. Through
sustained development of the CancerRx app, as well as continued advancement of
its other technologies and platforms, the company is positioning itself to
create a significant impact on the future of diagnostics and treatment options
for a multitude of life threatening conditions.
For
more information, visit www.collabrx.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
